Epidemiological and Economic Modelling of the Potential Impact of a Nicotine Vaccine on Smoking Cessation and Related Mortality and Morbidity in the Australian Population
Overview
Tobacco smoking is the risk factor that is responsible for the greatest burden on the health of Australians. It is estimated that 45% of all tobacco-related costs are potentially avoidable if tobacco smoking were to be eliminated. A novel treatment approach now under development to facilitate smoking cessation is a nicotine vaccine. The most promising clinical application of human nicotine vaccine is likely to be in relapse prevention in abstinent smokers. It may also have a role in preparing smokers to quit. Epidemiological and economic models will be developed to assess the potential impact of a nicotine vaccine on smoking prevalence and disease burden in the Australian population. If a nicotine vaccine looks promising in such modeling it may prove easier to find the public or private funding to evaluate its efficacy, apply for its registration and introduce it into clinical practice.
OPPE Staff
Angela Wallace and Wayne Hall
Collaborators
Theo Vos, Melanie Bertam
Status
In progress
Contact webmaster: oppe@uq.edu.au
Last updated: 1 September
2004